Salovey Peter purchased $183K of LEGN

Salovey Peter purchased 20,000 shares of Legend Biotech Corp (LEGN) at an average of $9.16 ($8.95–$9.38, $0.18M total) across 2 trades over 2026-11-12 to 2026-11-13.

Original reporting
SEC EDGAR · Salovey Peter
Published Nov 16, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LEGN
Neutral
medium confidence
Mentioned
$LEGN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LEGNNeutralLow
01

Why it matters

The disclosure adds incremental sentiment information but does not provide new guidance, trial results, regulatory decisions, or deal activity that would typically drive repricing.

02

Market read

Traders may note the insider buy as a mild positive signal, but the transaction size and lack of fundamental updates suggest limited trading edge.

03

What to watch

No 10b5-1 plan is stated, but the article also lacks context on prior holdings, compensation timing, or whether the purchase was part of a broader pattern.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-11-16, covering trades dated 2026-11-12 to 2026-11-13

Background

The article is an SEC Form 4 insider transaction disclosure for Legend Biotech director Salovey Peter.

Company-level read

Ticker impact

$LEGNNeutralMedium confidence
Context

Legend Biotech director Salovey Peter filed a Form 4 for an open-market purchase totaling $183,250 across 20,000 shares in mid-November.

Expected impact

Likely limited near-term impact, with any effect confined to sentiment rather than fundamentals.

Evidence & confidence

The filing is a director open-market purchase (not a 10b5-1 plan) but the disclosed dollar amount is modest and the article provides no new operational or financial catalyst.

Market effects

Minimal. Insider buying in a biotech does not, by itself, reset sector risk or valuation assumptions.

None indicated; this is a US-listed company insider transaction.

None indicated; no cross-border deal, regulator action, or macro linkage described.

Counterpoint

Director purchases can reflect diversification or routine liquidity needs rather than a bullish view on near-term fundamentals.

Key entities

  • Legend Biotech Corp

    US-listed biotech company (LEGN) whose director filed an insider purchase Form 4.

  • Salovey Peter

    Director who purchased 20,000 shares in two trades, totaling $183,250.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

$LEGNMedAI 8/10

Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.